Growth inhibitory effects of *Phyllanthus niruri* extracts in combination with cisplatin on cancer cell lines

Raimundo Fernandes de Araújo Júnior, Luiz Alberto Lira Soares, Cínthia Raquel da Costa Porto, Ranniere Gurgel Furtado de Aquino, Hugo Gonçalo Guedes, Pedro Ros Petrovick, Tatiane Pereira de Souza, Aurigena Antunes de Araújo, Gerlane Coelho Bernardo Guerra

Raimundo Fernandes de Araújo Júnior, Ranniere Gurgel Furtado de Aquino, Hugo Gonçalo Guedes, Department of Morphology/Postgraduate Program in Morphological Sciences, Federal University of Rio Grande do Norte, Natal 59072-970, Rio Grande do Norte, Brazil

Luiz Alberto Lira Soares, Postgraduate Program in Pharmaceutical Sciences, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil

Cínthia Raquel da Costa Porto, Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59012-570, Rio Grande do Norte, Brazil

Pedro Ros Petrovick, Department of Production and control of drugs, Federal University of Rio Grande do Sul, Porto Alegre 90610-000, Porto Alegre, Brazil

Tatiane Pereira de Souza, Department of Food and Drug Administration, Federal University of Amazonas, Manaus 69077-000, Amazonas, Brazil

Aurigena Antunes de Araújo, Gerlane Coelho Bernardo Guerra, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal 59072-970, Rio Grande do Norte, Brazil

Author contributions: Araújo Júnior RF and Guerra GCB designed the research; Araújo Júnior RF, Araújo AA and Guerra GCB performed the research; Soares LAL, Petrovick PR and de Souza TP contributed new reagents/analytic tools; Araújo Júnior RF, Guedes HG, da Costa Porto CR, Araújo AA, Guerra GCB wrote the paper. Supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); CNPq (470179/2009-0) for financial support and Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte.

Correspondence to: Gerlane Coelho Bernardo Guerra, PhD, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal 59072-970, Rio Grande do Norte, Brazil. gerlane@ugcn.com

Telephone: +55-84-32153419 Fax: +55-84-33422200

Received: July 6, 2011 Revised: January 10, 2012

Accepted: May 12, 2012 Published online: August 21, 2012

**Abstract**

**AIM:** To investigate the cytotoxic effects of spray-dried extracts of *Phyllanthus niruri* in combination with cisplatin on two cancer cell lines.

**METHODS:** Colorectal carcinoma (HT29) and human hepatocellular carcinoma (HepG2) cells were treated with spray-dried extracts of *Phyllanthus niruri* (SDEPN) either alone or in combination with cisplatin at different concentrations (0.5 mg/mL and 1 mg/mL) for 4 h and 24 h. To verify and quantify cancer cells treated with these products as well as identify the cell cycle stage and cell viability, we stained the cells with propidium iodide and assessed them by flow cytometry. The percentage of cells in different cell cycle phases was quantified and data were expressed as histograms. Significant differences between groups were determined using analysis of variance and Bonferroni’s test, as indicated. A value of *P* < 0.05 was considered to be statistically significant.

**RESULTS:** SDEPN had significantly different cytotoxic effects on HT29 (2.81 ± 0.11 vs 3.51 ± 1.13, *P* > 0.05) and HepG2 (5.07 ± 0.3 vs 15.9 ± 1.04, *P* < 0.001) cells when compared to control cells for 4 h. SDEPN also had significantly different cytotoxic effects on HT29 (1.91 ± 0.57 vs 4.53 ± 1.22, *P* > 0.05) and HepG2 (14.56 ± 1.6 vs 35.67 ± 3.94, *P* < 0.001) cells when compared to control cells for 24 h. Both cell lines were killed by cisplatin in a dose-dependent manner compared to control cells (HepG2 cells for 4 h: 10.78 ± 1.58 vs 53.89 ± 1.53, *P* < 0.001; 24 h: 8.9 ± 1.43 vs 62.78 ± 1.87, *P* < 0.001 and HT29 cells for 4 h: 9.52 ± 0.913 vs 49.86 ± 2.89, *P* < 0.001; 24 h: 11.78 ± 1.05 vs 53.34 ± 2.65, *P* < 0.001). In HT29 cells, pretreatment with SDEPN and subsequent treatment with cis-
Phyllanthus niruri has many effective traditional uses for a wide variety of diseases. Some of the medicinal uses have been supported in experimental models, suggesting that the plant extracts possess various pharmacological properties. Due to its impressive preclinical therapeutic potential, extracts of species of the genus Phyllanthus have been evaluated to treat hypertension, jaundice, diabetes, hypercalcemia, and urolithiasis[1]. Other studies revealed preclinical pharmacological and therapeutic potential of phytochemicals isolated from Phyllanthus niruri. The species has demonstrated an antimutagenic and anticarcinogenic action[2], antitumor[3], antioxidant[4], hepatoprotective[5,6] and antihyperemic properties[7], as well as antihyperlipemic activity[8].

Phytochemicals exhibit different structural characteristics with various pharmacological actions. For example, lignans have excellent hepatoprotective[9,10] and anti-viral properties[11], whereas terpenes exhibit anti-microbial activities[12]. Flavonoids from Phyllanthus niruri have been shown to have antioxidative[13], anti-inflammatory[14], and anti-carcinogenic[15] properties. Phytochemical studies have shown that extracts of genus Phyllanthus contain a variety of components, including gallic acid[16,17]. Furthermore, studies have demonstrated cytotoxic activity of gallic acid on the human promyelocytic leukemia HL-60 cell lines[18,19]. Gallic acid has also been shown to induce apoptotic cell death in HSC-2 and HL-60 cells[20].

More importantly, no side effects or toxicities have been reported for this herb after many years of research. Although extensive research has been conducted, there is still an abundance of unanswered questions regarding Phyllanthus niruri, particularly towards understanding the mechanism of biological activity of phytochemicals from the herb with emphasis on components that have anti-human immunodeficiency virus (HIV)[21] and anti-hepatitis B[22] properties. Phyllanthus niruri has been found to exhibit a marked inhibitory effect on the hepatitis B virus, as evidenced by its usefulness in patients cases of chronic jaundice. However, to date, no research has focused on the identification and validation of active pharmacophores of Phyllanthus niruri that are responsible for the reported inhibitory effect of its aqueous extract on HIV[23]. Investigations have examined anti-HIV effects of the alkaloidal extract from Phyllanthus niruri on human cell lines. An alkaloidal extract of Phyllanthus niruri showed suppressive activity on strains of HIV-1 cultured on the huT-4 cell line[24].

Directed studies of botanical extracts may lead to the discovery of new agents with improved and intriguing pharmacological properties. This may be achieved by molecular modeling studies that assess the interactions of bioactive phytochemicals from Phyllanthus niruri with their respective molecular targets. Moreover, upon improvement of binding affinity to the specified target by virtual chemical modification of existing pharmacophores, new small molecules may be identified and synthesized in the laboratory[25].

Other species of the genus Phyllanthus, such as Phyllanthus polyphyllus and Phyllanthus emblica, have demonstrated growth inhibitory activity with a certain degree of selectivity towards the two cancer cell lines tested. It has been previously shown that cisplatin can inhibit the growth of colorectal carcinoma (HT-29) and human hepatocellular carcinoma (HepG2) cells in a dose-dependent manner[20,24,25].

In this study, we investigated the antiproliferative or cell-killing activities of spray-dried extracts of Phyllanthus niruri on the human colorectal carcinoma HT-29 and human hepatocellular HepG2 cell lines. In addition, we assessed the capacity of these extracts to potentiate the action of cis-diaminedichloroplatinum II (cisplatin).

**INTRODUCTION**

Phyllanthus niruri has many effective traditional uses for a wide variety of diseases. Some of the medicinal uses have been supported in experimental models, suggesting that the plant extracts possess various pharmacological properties. Due to its impressive preclinical therapeutic potential, extracts of species of the genus Phyllanthus have been evaluated to treat hypertension, jaundice, diabetes, hypercalcemia, and urolithiasis[1]. Other studies revealed preclinical pharmacological and therapeutic potential of phytochemicals isolated from Phyllanthus niruri. The species has demonstrated an antimutagenic and anticarcinogenic action[2], antitumor[3], antioxidant[4], hepatoprotective[5,6] and antihyperemic properties[7], as well as antihyperlipemic activity[8].

Phytochemicals exhibit different structural characteristics with various pharmacological actions. For example, lignans have excellent hepatoprotective[9,10] and anti-viral properties[11], whereas terpenes exhibit anti-microbial activities[12]. Flavonoids from Phyllanthus niruri have been shown to have antioxidative[13], anti-inflammatory[14], and anti-carcinogenic properties[15]. Phytochemical studies have shown that extracts of genus Phyllanthus contain a variety of components, including gallic acid[16,17]. Furthermore, studies have demonstrated cytotoxic activity of gallic acid on the human promyelocytic leukemia HL-60 cell lines[18,19]. Gallic acid has also been shown to induce apoptotic cell death in HSC-2 and HL-60 cells[20].

More importantly, no side effects or toxicities have been reported for this herb after many years of research. Although extensive research has been conducted, there is still an abundance of unanswered questions regarding Phyllanthus niruri, particularly towards understanding the mechanism of biological activity of phytochemicals from the herb with emphasis on components that have anti-human immunodeficiency virus (HIV)[21] and anti-hepatitis B[22] properties. Phyllanthus niruri has been found to exhibit a marked inhibitory effect on the hepatitis B virus, as evidenced by its usefulness in patients cases of chronic jaundice. However, to date, no research has focused on the identification and validation of active pharmacophores of Phyllanthus niruri that are responsible for the reported inhibitory effect of its aqueous extract on HIV[23]. Investigations have examined anti-HIV effects of the alkaloidal extract from Phyllanthus niruri on human cell lines. An alkaloidal extract of Phyllanthus niruri showed suppressive activity on strains of HIV-1 cultured on the huT-4 cell line[24].

Directed studies of botanical extracts may lead to the discovery of new agents with improved and intriguing pharmacological properties. This may be achieved by molecular modeling studies that assess the interactions of bioactive phytochemicals from Phyllanthus niruri with their respective molecular targets. Moreover, upon improvement of binding affinity to the specified target by virtual chemical modification of existing pharmacophores, new small molecules may be identified and synthesized in the laboratory[25].

Other species of the genus Phyllanthus, such as Phyllanthus polyphyllus and Phyllanthus emblica, have demonstrated growth inhibitory activity with a certain degree of selectivity towards the two cancer cell lines tested. It has been previously shown that cisplatin can inhibit the growth of colorectal carcinoma (HT-29) and human hepatocellular carcinoma (HepG2) cells in a dose-dependent manner[20,24,25].

In this study, we investigated the antiproliferative or cell-killing activities of spray-dried extracts of Phyllanthus niruri on the human colorectal carcinoma HT-29 and human hepatocellular HepG2 cell lines. In addition, we assessed the capacity of these extracts to potentiate the action of cis-diaminedichloroplatinum II (cisplatin).

**MATERIALS AND METHODS**

**Preparation of Phyllanthus niruri spray dried extracts**

A spray-dried extract of Phyllanthus niruri (SDEPN) containing 12.33 mg/g of gallic acid[24] and 94.4 mg/g of total flavonoids[24] was prepared following the manufacturer’s instructions using a Spray Dryer Production Minor (GEA Niro, Denmark).

**Cell culture**

The human colorectal cancer cell line HT-29 and human hepatocellular carcinoma cell line HepG2 were
against the cancer cells tested. We therefore hypothesized that the combination of these plant extracts with chemotherapeutic drugs may have a synergistic cytotoxic effect on these cells. Primary flow cytometry analyses are shown in Figure 2.

**The effect of cisplatin on HT29 and HepG2 cells**

Using flow cytometry, we assessed the effects of cisplatin on the proliferation of HepG2 and HT29 cells. Both cell lines were killed in a dose-dependent manner compared to control cells (HepG2 cells for 4 h: 10.78 ± 1.58 vs. 53.89 ± 1.53, P < 0.001; 24 h: 8.9 ± 1.43 vs. 62.78 ± 1.87, P < 0.001 and HT29 cells for 4 h: 9.52 ± 0.913 vs. 49.86 ± 2.89, P < 0.001; 24 h: 11.78 ± 1.05 vs. 53.34 ± 2.65, P < 0.001; Figure 1). Primary flow cytometry analyses are shown in Figure 2.

**The combination of cisplatin and Phyllanthus niruri extracts has a synergistic cytotoxic effect on HT29 and HepG2 cells**

HT29 cells did not undergo cell death when SDEPN was used alone (P > 0.05) but HepG2 cells (P < 0.001) showed significant cell killing with treatment with SDEPN alone (Figure 1), but also very significantly (12.87 ± 2.78 vs. 78.8 ± 3.02, P < 0.001) when combined with cisplatin (Figure 1). However, HT29 cells underwent cell death (12.78 ± 1.01 vs. 93.76 ± 1.6, P < 0.001) when treated with SDEPN for 24 h prior to cisplatin treatment (Figure 1). The primary images of flow cytometry analysis can be seen in Figure 2.

In HT29 cells, pretreatment with SDEPN and subsequent treatment with cisplatin resulted in a greater number of cells being killed compared to treatment with cisplatin alone (Figure 1A and B). This increase in the number of HepG2 cells killed in response to combination treatment was observed at the lower concentration of SDEPN (Figure 1C and D). Therefore, pretreatment with SDEPN allowed the cells (HT29) to be sensitized to killing induced by cisplatin. This suggests that this cell type is more able to adapt to stressful conditions.

**DISCUSSION**

In this study, the growth inhibitory activity of SDEPN extract alone and in combination with cisplatin was investigated in HT29 and HepG2 cells. Our results indicated that SDEPN extract significantly inhibited the growth of both cell lines in a dose-dependent manner when combined with cisplatin.

Cisplatin is a well-known cancer therapeutic agent that causes high toxicity to normal tissues during cancer therapy, inducing cell death through interaction of the platinum complex with DNA molecules which induces crosslinking in DNA[28,29]. The platinum compound is used to treat various types of human solid tumors[30]. The major limitation to clinical use of cisplatin is the adverse effects, mainly nephrotoxicity, caused by the compound[31]. In addition to DNA interactions, cisplatin

---

**RESULTS**

**Cytotoxic effects of SDEPN on HT29 and HepG2 cells**

The effects of SDEPN on cell killing in two cancer cell lines were determined by flow cytometry. All cell lines were killed in a dose-dependent manner after exposure to the plant extracts (Figure 1). SDEPN had significantly different cytotoxic effects on HT29 (2.81 ± 0.11 vs. 3.51 ± 1.13, P > 0.05) and HepG2 (5.07 ± 0.3 vs. 15.9 ± 1.04, P < 0.001) cells when compared to control cells for 4 h. SDEPN also had significantly different cytotoxic effects on HT29 (1.91 ± 0.57 vs. 4.53 ± 1.22, P > 0.05) and HepG2 (14.56 ± 1.6 vs. 35.67 ± 3.94, P < 0.001) cells when compared to control cells for 24 h. These results indicated that the plant extract was selectively toxic against the cancer cells tested. We therefore hypothesized that the combination of these plant extracts with chemotherapeutic drugs may have a synergistic cytotoxic effect on these cells. Primary flow cytometry analyses are shown in Figure 2.
is capable of generating oxidative stress through mitochondrial dysfunction, which results in the increased production of reactive oxygen species (ROS)\(^3\). Therefore, our data show that HT29 cells are more resistant to SDEPN- or cisplatin-mediated cell death, and this resistance may be related to their ability to adapt to stressful conditions. In addition, HepG2 cells were more sensitive to both treatments, suggesting that these cells may be less adapted to stress. In this study we found that the combination of SDEPN with cisplatin induced growth inhibition and cell death at different dose levels in HT29 and HepG2 cell lines.

The mechanism of action of some plant extracts is still unclear, since they are not a single active ingredient but rather consist of multiple compounds that could potentially induce the observed effects\(^1,2\). Plant-derived polyphenols, including gallic acid\(^3,4\) and tannins\(^5\), were reported to be the main components of Phyllanthus niruri extracts\(^1\). Therefore, the effects of SDEPN may induce apoptosis and cell death in the cell lines used in this study through multiple pathways due to the multiple components present in the extract. The active ingredients in Phyllanthus niruri that exert anticancer effects may include polyphenols, such as gallic acid, flavanoids or tannins, which are abundant in the herb. However, the detailed mechanism responsible for the anticancer effect of SDEPN extract and identification of the actual functional components require further elucidation.

It has been previously demonstrated that the effect of gallic acid on cancer cells, particularly lung cancer cells, involves caspase activation and oxidative processes\(^6\). In addition, gallic acid has the capacity to induce apoptosis and increase the efficacy of cisplatin in LL-2 lung cancer cells\(^7\).

Our study provides corroborative evidence that SDEPN has selective cytotoxic effects against HT29 and HepG2
Moreover, a synergistic effect was seen when the cells were treated with the extract in combination with cisplatin. This finding supports our hypothesis that combinations of plant extracts and chemotherapeutic agents may allow for a reduction in the dosage of the more toxic chemotherapeutic agent while retaining the therapeutic efficacy and minimizing toxicities. The induction of cell death by SDEPN may increase the sensitivity of HT29 cells to cisplatin-mediated cytotoxicity. Other species of the genus *Phyllanthus* have demonstrated growth inhibitory activity with a certain degree of selectivity towards the two cancer cell lines tested.

The findings of this study support our hypothesis that combinations of plant extracts and chemotherapeutic agents allow for a reduction in the dosage of the latter (i.e., cisplatin), while maintaining therapeutic efficacy. Moreover, the induction of cell death by SDEPN may be a strategy for increasing the sensitivity of HT29 cells to cisplatin-mediated cell death.

**COMMENTS**

**Background**

*Phyllanthus niruri* is a widespread tropical plant that is commonly found in coastal areas of Mexico, Argentina, and Brazil. In Brazil, some plant extracts have been distributed to patients by the Public Health Programme since 2010.
as an adjunctive therapy for various diseases. The extract from aerial sections of Phyllanthus niruri was included in this list due to the long history of use in traditional medicine for the treatment of kidney and bladder diseases, intestinal infections, diabetes, and hepatitis B. Furthermore, this study has demonstrated an in vitro pro-death potential in cancer cells when Phyllanthus niruri is associated with cisplatin. In vivo studies are still needed to confirm our findings.

**Research frontiers**

Currently, a variety of effective phytochemicals have been tested in cancer treatment, which are used alone or in combination with chemotherapeutic agents for treatment. A spray-dried extract from Phyllanthus niruri (SDEPN) was found to be selectively toxic against two cancer cell lines and induced an increase in cell death of HT29 and HepG2 cells when used in combination with cisplatin. HT29 cells did not undergo cell death when SDEPN was used alone. The mechanism of this effect is currently unknown, but may involve apoptosis, since a major component of SDEPN extract is gallic acid, which has been shown to induce apoptotic pathways.

**Innovations and breakthroughs**

In this report, the authors have demonstrated that combinations of SDEPN with cisplatin in HT29 and HepG2 cell lines have a more potent effect than either agent alone.

**Applications**

Spray-dried extract of SDEPN appears to be cytotoxic against hepatocellular carcinoma and less toxic against colorectal carcinoma. A combination of SDEPN extract with a chemotherapeutic agent may therefore enhance the efficacy of each component against these cancers. Future in vivo studies will be performed by our group to study the anticancer activity of SDEPN alone and in combination with cisplatin as well as the toxicity against normal tissues.

**Terminology**

Dried herbal extracts are widely used as therapeutic products with improved pharmaceutical properties, such as stability and content uniformity. Additionally, dried extracts are successfully used to obtain solid dosage forms that contain a high dose of herbal extracts, such as capsules and tablets. Therefore, spray drying is the most commonly used procedure to obtain dried extracts (spray-dried extracts) in the herbal processing industry.

**Peer review**

The manuscript is well written and the findings are interesting to some extent. However, some concerns need to be addressed.

**REFERENCES**

13. Popova MP, Chinou IB, Marekov IN, Bankova VS. Terpenes with antimicrobial activity from Cretan propolis. *Phytochemistry 2009; 70: 1262-1271*
22. Sarkar MK, Sil PC. Hepatocytes are protected by herb Phyllanthus niruri protein isolate against thioacetamide toxicity. *Pathophysiology 2007; 14: 113-120*
30 Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006; 44: 1173-1183
32 Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 2008; 28: 337-344

S- Editor Gou SX L- Editor Kerr C E- Editor Zhang DN